Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Holdings Boosted by EFG Asset Management North America Corp.

EFG Asset Management North America Corp. grew its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 30.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 43,157 shares of the company’s stock after purchasing an additional 10,087 shares during the quarter. EFG Asset Management North America Corp.’s holdings in Apellis Pharmaceuticals were worth $1,378,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its stake in Apellis Pharmaceuticals by 1.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 956,362 shares of the company’s stock worth $27,581,000 after buying an additional 9,328 shares during the last quarter. Cerity Partners LLC boosted its holdings in shares of Apellis Pharmaceuticals by 311.2% during the third quarter. Cerity Partners LLC now owns 31,381 shares of the company’s stock valued at $905,000 after acquiring an additional 23,749 shares during the period. BNP Paribas Financial Markets grew its position in shares of Apellis Pharmaceuticals by 52.9% during the third quarter. BNP Paribas Financial Markets now owns 159,700 shares of the company’s stock worth $4,606,000 after acquiring an additional 55,282 shares during the last quarter. FORA Capital LLC acquired a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter worth about $422,000. Finally, Braidwell LP increased its holdings in shares of Apellis Pharmaceuticals by 410.8% in the 3rd quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock worth $90,130,000 after acquiring an additional 2,513,383 shares during the period. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Wedbush reduced their target price on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. JPMorgan Chase & Co. boosted their price objective on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 4th. Royal Bank of Canada lowered their target price on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating on the stock in a research report on Monday, March 3rd. The Goldman Sachs Group reduced their price target on Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Finally, HC Wainwright reissued a “buy” rating and set a $57.00 price target on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $45.53.

Insider Buying and Selling

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 5,569 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total value of $139,781.90. Following the completion of the transaction, the general counsel now directly owns 138,730 shares in the company, valued at $3,482,123. This trade represents a 3.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $28.70, for a total transaction of $62,279.00. Following the completion of the transaction, the chief financial officer now directly owns 88,100 shares in the company, valued at approximately $2,528,470. This trade represents a 2.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 66,054 shares of company stock worth $1,952,719 in the last three months. 6.80% of the stock is currently owned by insiders.

Apellis Pharmaceuticals Stock Performance

Shares of APLS opened at $23.76 on Wednesday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The firm’s 50 day moving average is $27.37 and its 200-day moving average is $29.78. Apellis Pharmaceuticals, Inc. has a 12-month low of $23.37 and a 12-month high of $59.91. The stock has a market capitalization of $2.98 billion, a P/E ratio of -11.70 and a beta of 0.92.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. During the same quarter in the previous year, the business posted ($0.73) earnings per share. The firm’s quarterly revenue was up 45.2% compared to the same quarter last year. Equities research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).